The combination of stroma normalization + vascular normalization + anti-VEGF producing FAP-CAR-T cells can potentially improve survival, even if the CAR-T cells are injected after the optimum time point (Fig. 7A) because the tumor volume does not increase as rapidly as in the case of anti-VEGF + anti-VEGF producing CAR-T cells (Fig. 6A). This evidence concerns the gene VEGFA and neoplasm.